CTGov Compliance My Organizations

Compliance Rate

Compliance Rate 0%

Compliant submissions 0

Incompliant submissions 0

Total trials 0

Showing 4 of 4 entries

View as:

Phase: N/A Priority: Normal

NCT ID: NCT01725256 Org: User:

Start: 11/30/12 End: 02/28/14 Due: 02/28/15

Phase: N/A Priority: Normal

NCT ID: NCT00814645 Org: User:

Start: 12/31/08 End: 06/30/09 Due: 06/30/10

Phase: N/A Priority: Normal

NCT ID: NCT01725269 Org: User:

Start: 03/31/13 End: 04/30/14 Due: 04/30/15

Phase: N/A Priority: Normal

NCT ID: NCT01409122 Org: User:

Start: 07/31/11 End: 01/31/12 Due: 01/31/13

Title	NCT ID	Organization	User	Status	Start Date	End Date	Reporting Due Date	Last Checked	User Role	Org Created
A Phase 2 Study to Determine the Safety and Efficacy of AIR001 in Subjects With Pulmonary Arterial Hypertension (PAH)	NCT01725256	Aires Pharmaceuticals, Inc.	user2@example.com	None	2012-11-30	2014-02-28	2015-02-28	-	-	2025-07-14
Dose-Finding, Safety, Pharmacodynamic Effect Study of Sodium Nitrite Inhalation Solution in Normal, Healthy Volunteers	NCT00814645	Aires Pharmaceuticals, Inc.	user2@example.com	None	2008-12-31	2009-06-30	2010-06-30	-	-	2025-07-14
Long-term Study of AIR001 in Subjects With WHO Group 1 Pulmonary Arterial Hypertension Who Completed AIR001-CS05	NCT01725269	Aires Pharmaceuticals, Inc.	user2@example.com	None	2013-03-31	2014-04-30	2015-04-30	-	-	2025-07-14
Safety, Tolerability, and PK Parameters of Sodium Nitrite Inhalation Solution in Healthy Subjects	NCT01409122	Aires Pharmaceuticals, Inc.	user2@example.com	None	2011-07-31	2012-01-31	2013-01-31	-	-	2025-07-14